 | |
Native name | 長江生命科技集團有限公司 |
|---|---|
| Company type | Public |
| SEHK: 775 | |
| Industry | Biotechnology |
| Founded | 2000 |
| Headquarters | |
Area served | Hong Kong |
Key people | Chairman: Mr. Victor Li |
| Products | Lifce Sciences products |
| Services | Life Sciences |
| Parent | Cheung Kong Holdings |
| Website | www |
CK Life Sciences International (Holdings) Inc. (Chinese: 長江生命科技集團有限公司), or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products.[1] The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002 (Former stock code: SEHK: 8222). It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company (Cheetham Salt) as part of its expansion into the agricultural sector.[2]
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024.[3]
- ^ "CK Life Sciences Intl (Holdings) Inc". Reuters. Retrieved 27 June 2018.
- ^ Shih, Toh Han (30 November 2012). "CK Life Sciences buys Australia's Cheetham Salt for A$150m". South China Morning Post. Retrieved 27 June 2018.
- ^ Lee, Zinnia (8 October 2024). "Unit Of Li Ka-Shing's CK Life Sciences To Merge With Nasdaq-Listed Biotech Company In $100 Million Deal". Forbes.